Table 1.
Top canonical pathways from the IPA knowledge base that involve proteins differentially expressed in young compared with old chondrogenic, tenogenic and osteogenic constructs
| Construct | Pathway | p value | Ratio |
|---|---|---|---|
| Chondrogenica | LXR/RXR activation | 6.01 × 10–7 | 8/121 (0.066) |
| FXR/RXR activation | 8.69 × 10–7 | 8/127 (0.062) | |
| Acute phase response signalling | 7.36 × 10–6 | 8/169 (0.047) | |
| Cholesterol biosynthesis I | 5.49 × 10–5 | 3/13 (0.231) | |
| Cholesterol biosynthesis II | 5.49 × 10–5 | 3/13 (0.231) | |
| Tenogenica | Glycolysis I | 5.15 × 10–9 | 7/25 (0.28) |
| Gluconeogenesis I | 1.85 × 10–7 | 6/25 (0.24) | |
| ILK signalling | 6.45 × 10–7 | 12/186 (0.065) | |
| Mitochondrial dysfunction | 1.96 × 10–6 | 11/171 (0.064) | |
| Protein ubiquitination pathway | 3.10 × 10–6 | 13/255 (0.051) | |
| Osteogenicb | Mitochondrial dysfunction | 1.29 × 10–4 | 5/171 (0.029) |
| Lipid antigen presentation by CD1 | 2.51 × 10–3 | 2/26 (0.077) | |
| Integrin signalling | 2.68 × 10–3 | 4/202 (0.02) | |
| Oxidative phosphorylation | 3.79 × 10–3 | 3/109 (0.028) | |
| Glycerol-3-phosphate shuttle | 8.58 × 10–3 | 1/3 (0.333) |
aSignificant DE proteins with p < 0.05, q < 0.05 and ±2-fold change
bSignificant DE proteins with p < 0.05 and ±2-fold change
DE differentially expressed, IPA ingenuity pathway analysis